![hoffmann6383's tweet photo. 📢📢$NWBO Acquires Advent Bioservices
https://t.co/ud6uYmesP7
$NWBO acquires Advent for $1.4m‼️
What does this accomplish?
➡️Management Team Expansion
Headcount just went from ~20 (ish) $NWBO employees to likely 100+ total employees. As you will see from Linda Powers comment at the ASM, a goal was to expand the management team. This is certainly a step in the right direction as it gives $NWBO a much larger pool of employees to take on expanded roles. Image 1 shows Advent's headcount at the end of '23 being 73 employees.
Linda Powers at 2023 ASM, held June 29, 2024, stated, in relevant part:
"And very dear to our hearts, we need to expand the management team. We need to expand the management team rather substantially. As you probably have guessed, and as we described in the proxy, each of the core members of the senior team has been wearing multiple hats, has been fulfilling multiple roles. And I mean, multiple roles that would each be normally a separate senior management person at other companies. And I'm really proud that we've been able to do that, but we need to we need to ramp up. We we've got tremendous opportunity, and we need to ramp up. So that is going to be a significant focus for us, as soon as we can achieve it. We wanna be highly selective, but we plan to substantially expand the management team." [1]
➡️A revenue steam to potentially help obtain standard bank financing
I believe this puts $NWBO in a position to obtain standard bank financing based off of Advent's revenue stream. This should help slow future dilution. As you can see, Advent's financial statement (Image 1) shows about $27.5m USD in revenue for '23, which was a 23% increase over '22. [2] A more modest 15% growth rate would give them nearly $32m in revenue for '24. I believe this should allow $NWBO to be eligible for standard bank financing. Hats off to the late Les Goldman for getting us to this point by tirelessly raising funds from retail and institutional investors.
➡️What was the value of Advent?
Recall, Cognate BioServices, Inc. sold for $875m on projected revenue of $140m for the year, a 6.25 multiple of revenue (I know, I know, a really quick and sloppy way of looking at it). [3] Say Advent is up to $40m in revenue and using the same multiple it gives a value of $250m.
➡️Big Money more receptive to investments
$NWBO has largely survived on the backs of retail investors to date. To attract more institutional investors and even potentially a buyer, $NWBO needed to undo some entanglements and become more transparent. While the Advent/$NWBO related party relationship was legal, it created some complicated dynamics that could have scared off the bigger investors. With today's acquisition of Advent, $NWBO just became more attractive to deeper pockets, whether investing or acquiring. This was the first, and the biggest, domino that had to fall in this regard. Great first step.
➡️Another deceptive Adam Feuerstein narrative bites the dust
See Image 3.
Mr. Feuerstein needs to, at the very least, add another line (or two) to his graphic:
Shareholder money -> NWBO -> Advent -> Linda Powers [insert additions] -> NWBO -> Shareholders
[1]https://t.co/3wNfuUaROE
[2]https://t.co/jlZS4ceQTA"08717711_aa_2025-03-04.pdf"&X-Amz-Signature=42d084f11a9fd893890cea368d750d572ffe089449d946904fda5f66a33ee978
[3]https://t.co/Jb2l9TNvmy](https://pbs.twimg.com/media/GzX4wIJXcAA1meO.png)
![hoffmann6383's tweet photo. 📢📢$NWBO Acquires Advent Bioservices
https://t.co/ud6uYmesP7
$NWBO acquires Advent for $1.4m‼️
What does this accomplish?
➡️Management Team Expansion
Headcount just went from ~20 (ish) $NWBO employees to likely 100+ total employees. As you will see from Linda Powers comment at the ASM, a goal was to expand the management team. This is certainly a step in the right direction as it gives $NWBO a much larger pool of employees to take on expanded roles. Image 1 shows Advent's headcount at the end of '23 being 73 employees.
Linda Powers at 2023 ASM, held June 29, 2024, stated, in relevant part:
"And very dear to our hearts, we need to expand the management team. We need to expand the management team rather substantially. As you probably have guessed, and as we described in the proxy, each of the core members of the senior team has been wearing multiple hats, has been fulfilling multiple roles. And I mean, multiple roles that would each be normally a separate senior management person at other companies. And I'm really proud that we've been able to do that, but we need to we need to ramp up. We we've got tremendous opportunity, and we need to ramp up. So that is going to be a significant focus for us, as soon as we can achieve it. We wanna be highly selective, but we plan to substantially expand the management team." [1]
➡️A revenue steam to potentially help obtain standard bank financing
I believe this puts $NWBO in a position to obtain standard bank financing based off of Advent's revenue stream. This should help slow future dilution. As you can see, Advent's financial statement (Image 1) shows about $27.5m USD in revenue for '23, which was a 23% increase over '22. [2] A more modest 15% growth rate would give them nearly $32m in revenue for '24. I believe this should allow $NWBO to be eligible for standard bank financing. Hats off to the late Les Goldman for getting us to this point by tirelessly raising funds from retail and institutional investors.
➡️What was the value of Advent?
Recall, Cognate BioServices, Inc. sold for $875m on projected revenue of $140m for the year, a 6.25 multiple of revenue (I know, I know, a really quick and sloppy way of looking at it). [3] Say Advent is up to $40m in revenue and using the same multiple it gives a value of $250m.
➡️Big Money more receptive to investments
$NWBO has largely survived on the backs of retail investors to date. To attract more institutional investors and even potentially a buyer, $NWBO needed to undo some entanglements and become more transparent. While the Advent/$NWBO related party relationship was legal, it created some complicated dynamics that could have scared off the bigger investors. With today's acquisition of Advent, $NWBO just became more attractive to deeper pockets, whether investing or acquiring. This was the first, and the biggest, domino that had to fall in this regard. Great first step.
➡️Another deceptive Adam Feuerstein narrative bites the dust
See Image 3.
Mr. Feuerstein needs to, at the very least, add another line (or two) to his graphic:
Shareholder money -> NWBO -> Advent -> Linda Powers [insert additions] -> NWBO -> Shareholders
[1]https://t.co/3wNfuUaROE
[2]https://t.co/jlZS4ceQTA"08717711_aa_2025-03-04.pdf"&X-Amz-Signature=42d084f11a9fd893890cea368d750d572ffe089449d946904fda5f66a33ee978
[3]https://t.co/Jb2l9TNvmy](https://pbs.twimg.com/media/GzX4wIFWEAAar28.png)
Olivia
Online
maybe:
@otcgh0st
otcgh0st because my gains are invisible - don’t listen to me
Minnesota, USA
Joined May 2020
460 Following
283 Followers
831 Posts
@Doug_Cartwright @TMZ Doug, if you haven’t already, look into DC-Vax by Northwest Biotheraputics. Dendritic cell vaccine made from your own tumor. Many success stories with this treatment. $nwbo
@FlemmingBruce Bruce, love the idea and joined! Thank you for doing this.
My only worry is that if we stop supporting NWBO on other platforms, the FUD takes over. Unfortunately X, liehub, etc are still popular amongst other investors, so if NWBO longs and supporters leave, only FUD will exist
@SouthernDrive21 Are we expecting NWBO to be involved/mentioned in any further CHM meetings? Correct me if I’m wrong, but the last CHM meeting where DCVAX was discussed was Nov25, right?
Who to follow
Ched R Pops 
@ChedPops
Be an oak ! SPY degen not investing advice.Technical Analysis 1st. Expect the unexpected. ✝️ +🙏🏻
🪙 DUKE KaBOOM 🔱 👑👑💰💰💰
@Philips_247
𓃶 𓀐𓂸 𓀬 gains liason. please do your own due diligence.
make it rain, make it Rainnnn⛈️
#PerpeTraders #BlackVulture #Sweetspot
Schoencards
@BourbonInvestm2
Buying selling and collecting sports cards. Everyday is a gift! Life's a garden, dig it!
https://t.co/vxM6U8fXZg
@FlemmingBruce Never go full……. 🤫
@PJC3251 @gkittle46 @JoshAllenQB Ah damn, I saw he had 27.5 pts in the league I’m in. Maybe a different scoring format. Thought you had it in the bag!
$NWBO
“Beating brain cancer through vaccines and research”
DCVax-L mentioned by name.
“…The science behind the vaccine is surprisingly elegant.
Liau and her team found that by taking a patient’s own immune cells, exposing them in the lab to pieces of that person’s glioblastoma tumor, and then injecting them back into the patient, the immune system could be “taught” to recognize and attack the cancer.
Over a series of clinical trials, DCVax-L was shown to help extend the lives of people with newly diagnosed and recurrent glioblastoma — with some surviving far beyond the expected two-year expected survival for this diagnosis….”
@UCLAHealth
https://t.co/oniFIdjJpB
@metacollectiveG
@HockeyExpert98 @spittinchiclets
@GoneGoodguy 10-4. Ready for take off, over.
This bird could be yours‼️
RT for a chance to win
(18+) Rules/Eligibility ➡️ Link in bio
📢📢$NWBO Acquires Advent Bioservices
https://t.co/ud6uYmesP7
$NWBO acquires Advent for $1.4m‼️
What does this accomplish?
➡️Management Team Expansion
Headcount just went from ~20 (ish) $NWBO employees to likely 100+ total employees. As you will see from Linda Powers comment at the ASM, a goal was to expand the management team. This is certainly a step in the right direction as it gives $NWBO a much larger pool of employees to take on expanded roles. Image 1 shows Advent's headcount at the end of '23 being 73 employees.
Linda Powers at 2023 ASM, held June 29, 2024, stated, in relevant part:
"And very dear to our hearts, we need to expand the management team. We need to expand the management team rather substantially. As you probably have guessed, and as we described in the proxy, each of the core members of the senior team has been wearing multiple hats, has been fulfilling multiple roles. And I mean, multiple roles that would each be normally a separate senior management person at other companies. And I'm really proud that we've been able to do that, but we need to we need to ramp up. We we've got tremendous opportunity, and we need to ramp up. So that is going to be a significant focus for us, as soon as we can achieve it. We wanna be highly selective, but we plan to substantially expand the management team." [1]
➡️A revenue steam to potentially help obtain standard bank financing
I believe this puts $NWBO in a position to obtain standard bank financing based off of Advent's revenue stream. This should help slow future dilution. As you can see, Advent's financial statement (Image 1) shows about $27.5m USD in revenue for '23, which was a 23% increase over '22. [2] A more modest 15% growth rate would give them nearly $32m in revenue for '24. I believe this should allow $NWBO to be eligible for standard bank financing. Hats off to the late Les Goldman for getting us to this point by tirelessly raising funds from retail and institutional investors.
➡️What was the value of Advent?
Recall, Cognate BioServices, Inc. sold for $875m on projected revenue of $140m for the year, a 6.25 multiple of revenue (I know, I know, a really quick and sloppy way of looking at it). [3] Say Advent is up to $40m in revenue and using the same multiple it gives a value of $250m.
➡️Big Money more receptive to investments
$NWBO has largely survived on the backs of retail investors to date. To attract more institutional investors and even potentially a buyer, $NWBO needed to undo some entanglements and become more transparent. While the Advent/$NWBO related party relationship was legal, it created some complicated dynamics that could have scared off the bigger investors. With today's acquisition of Advent, $NWBO just became more attractive to deeper pockets, whether investing or acquiring. This was the first, and the biggest, domino that had to fall in this regard. Great first step.
➡️Another deceptive Adam Feuerstein narrative bites the dust
See Image 3.
Mr. Feuerstein needs to, at the very least, add another line (or two) to his graphic:
Shareholder money -> NWBO -> Advent -> Linda Powers [insert additions] -> NWBO -> Shareholders
[1]https://t.co/3wNfuUaROE
[2]https://t.co/jlZS4ceQTA"08717711_aa_2025-03-04.pdf"&X-Amz-Signature=42d084f11a9fd893890cea368d750d572ffe089449d946904fda5f66a33ee978
[3]https://t.co/Jb2l9TNvmy
![hoffmann6383's tweet photo. 📢📢$NWBO Acquires Advent Bioservices
https://t.co/ud6uYmesP7
$NWBO acquires Advent for $1.4m‼️
What does this accomplish?
➡️Management Team Expansion
Headcount just went from ~20 (ish) $NWBO employees to likely 100+ total employees. As you will see from Linda Powers comment at the ASM, a goal was to expand the management team. This is certainly a step in the right direction as it gives $NWBO a much larger pool of employees to take on expanded roles. Image 1 shows Advent's headcount at the end of '23 being 73 employees.
Linda Powers at 2023 ASM, held June 29, 2024, stated, in relevant part:
"And very dear to our hearts, we need to expand the management team. We need to expand the management team rather substantially. As you probably have guessed, and as we described in the proxy, each of the core members of the senior team has been wearing multiple hats, has been fulfilling multiple roles. And I mean, multiple roles that would each be normally a separate senior management person at other companies. And I'm really proud that we've been able to do that, but we need to we need to ramp up. We we've got tremendous opportunity, and we need to ramp up. So that is going to be a significant focus for us, as soon as we can achieve it. We wanna be highly selective, but we plan to substantially expand the management team." [1]
➡️A revenue steam to potentially help obtain standard bank financing
I believe this puts $NWBO in a position to obtain standard bank financing based off of Advent's revenue stream. This should help slow future dilution. As you can see, Advent's financial statement (Image 1) shows about $27.5m USD in revenue for '23, which was a 23% increase over '22. [2] A more modest 15% growth rate would give them nearly $32m in revenue for '24. I believe this should allow $NWBO to be eligible for standard bank financing. Hats off to the late Les Goldman for getting us to this point by tirelessly raising funds from retail and institutional investors.
➡️What was the value of Advent?
Recall, Cognate BioServices, Inc. sold for $875m on projected revenue of $140m for the year, a 6.25 multiple of revenue (I know, I know, a really quick and sloppy way of looking at it). [3] Say Advent is up to $40m in revenue and using the same multiple it gives a value of $250m.
➡️Big Money more receptive to investments
$NWBO has largely survived on the backs of retail investors to date. To attract more institutional investors and even potentially a buyer, $NWBO needed to undo some entanglements and become more transparent. While the Advent/$NWBO related party relationship was legal, it created some complicated dynamics that could have scared off the bigger investors. With today's acquisition of Advent, $NWBO just became more attractive to deeper pockets, whether investing or acquiring. This was the first, and the biggest, domino that had to fall in this regard. Great first step.
➡️Another deceptive Adam Feuerstein narrative bites the dust
See Image 3.
Mr. Feuerstein needs to, at the very least, add another line (or two) to his graphic:
Shareholder money -> NWBO -> Advent -> Linda Powers [insert additions] -> NWBO -> Shareholders
[1]https://t.co/3wNfuUaROE
[2]https://t.co/jlZS4ceQTA"08717711_aa_2025-03-04.pdf"&X-Amz-Signature=42d084f11a9fd893890cea368d750d572ffe089449d946904fda5f66a33ee978
[3]https://t.co/Jb2l9TNvmy](https://pbs.twimg.com/media/GzX4wIKWEAAlA9G.png)
$NWBO
a David vs Goliath battle against greed in its ugliest form - allegedly trying to destroy a small public company with a promising brain cancer treatment.
The Goliaths couldn't stop the market manipulation lawsuit and the case is now in discovery
"The parallels to The Big Short are uncanny.
... in both cases, the moral hazard is stark: in 2008, bankers grew rich while millions lost homes; in NWBO’s case, traders allegedly profited while patients waited for innovation
Tens of millions of baiting orders left investors believing the company was a penny stock with no demand.
Just as mortgage brokers kept selling loans that everyone knew would default, spoofing created the appearance of endless supply when real buyers existed
Every story has a crack-the-glass moment.
In 2008, it was Lehman Brothers’ collapse. By then, no one could deny the system was rotten. The house of cards collapsed, defaults cascaded, and the AAA labels were revealed as fiction.
For NWBO, that day was May 10, 2022.
The company presented statistically significant Phase 3 results for DCVax-L in glioblastoma—a therapy that, for the first time in decades, showed survival benefit in both newly diagnosed and recurrent disease.
In a rational market, that should have been the equivalent of Burry’s CDS paying out.
Instead, the stock collapsed 78 percent in a single day, from $1.73 to $0.3862.
The optics of May 10 echo Lehman.
It was the day reality and price diverged most violently.
A breakthrough therapy was priced as failure, just as AAA securities were priced as safe days before they collapsed
Discovery is now the turning point.
For Burry, vindication came when default data surged through the system.
For NWBO, it will come when order logs, code, and chat transcripts are revealed. If they show traders stacking and canceling orders with intent, the illusion is broken. It becomes not just a story of weak stock but of deliberate manipulation...."
-@andrewcaravello
____________
July 2025
Why doesn't the @MiamiHerald even mention that Ken Griffin's company, Citadel Securities, is being sued for alleged market manipulation by Northwest Biotherapeutics, which has a promising treatment for brain cancer??
https://t.co/H7ET9CZqGl
@metacollectiveG Wish the article was new….it’s from 2023 unfortunately
Hey @adamfeuerstein—
40 terminal patients.
13 cancers.
Phase 1 survival data.
NY Academy of Sciences.
Published systemic immune activation.
Multiple 3–4 year survivors.
You cover biotech, right?
Do your f*ing job.**
$NWBO
The Silence Before the Snap https://t.co/nyrn1TeqFd
@andrewcaravello @flaskworks @DCVaxDefender He’s had a lot of valuable & pro NWBO posts over the months. I’ve never seen him say a negative thing about NWBO. You guys may not see eye to eye on some details but I think it’s clear you both want the company to succeed. Again, just my 2 cents. Not saying I’m right/youre wrong
@andrewcaravello @flaskworks @DCVaxDefender Andrew, I value you, your posts, and insights, but the @flaskworks account hasn’t posted since March 2025 & aligns perfectly w/ when @DCVaxDefender started posting. Yes the DCVAXDefender account was created in 2024 but I dont think it’s uncommon for people to have backup accounts
Last Seen Users on Sotwe
Hyperspermia.co
Seen from France
Kay_rantt_
Seen from Vietnam
CLIP GAY HOT VN
Seen from Vietnam
sxec
Seen from Pakistan
Kiro
Seen from Malaysia
mbull
Seen from India
𝐐𝐮𝐞𝐞𝐧
Seen from Algeria
Mature 45+
Seen from Singapore
𝓓𝓸𝓷 𝓑𝓪𝓼𝓼
Seen from Latvia
cuckold bbc karısını paylaşanlar
Seen from Netherlands
Something went wrong.
Most Popular Users
Elon Musk
@elonmusk
240.5M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.4M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.6M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.9M followers
KATY PERRY
@katyperry
87.5M followers
Taylor Swift
@taylorswift13
81.4M followers
Lady Gaga
@ladygaga
72.9M followers
Kim Kardashian
@kimkardashian
69.7M followers
Virat Kohli
@imvkohli
69.7M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
63.8M followers
The Ellen Show
@theellenshow
62.5M followers
Neymar Jr
@neymarjr
62.4M followers
CNN
@cnn
61.9M followers
X
@x
60.8M followers
Selena Gomez
@selenagomez
60.6M followers